Tamoxifen, cytochrome P450 genes and breast cancer... [Breast. 2010] - PubMed result

Breast. 2010 Dec 23. [Epub ahead of print]
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.

Singh MS, Francis PA, Michael M.

Andrew Love Cancer Centre, Geelong, VIC 3220, Australia.

Abstract

Tamoxifen has a key role in the management of women with hormone receptor (HR) positive breast cancer. It is the endocrine treatment of choice in premenopausal women with HR positive breast cancer and is also clinically indicated in significant numbers of post-menopausal women who have relative contraindications to aromatase inhibitors. Tamoxifen is a pro-drug that is metabolised to its active metabolites by the cytochrome P450 (CYP) enzymes including CYP2D6, CYP3A, CYP2B6, and CYP2C19. The CYP genes are polymorphic resulting in variable enzyme activity. Retrospective clinical data suggests that specific single nucleotide polymorphisms (SNPs) of CYP2D6 can lead to null or reduced enzyme activity resulting in worse outcomes for those individuals when treated with tamoxifen for HR positive breast cancer. There is however a lack of robust prospective clinical data on this subject. Commercial tests are now available for the genotyping of CYP2D6 with the aim of individualisation of tamoxifen therapy for patients with HR positive breast cancer. Selective serotonin reuptake inhibitor antidepressant drugs such as paroxetine and fluoxetine have also been used to manage tamoxifen induced hot flushes. These drugs potently inhibit the metabolism of tamoxifen by CYP2D6 and thus potentially may lessen the efficacy of tamoxifen. The genetic variations in other enzymes involved in tamoxifen metabolism (CYP3A, CYP2B6, CYP2C19) do not appear to cause any meaningful difference in the efficacy of tamoxifen. This review article will summarize the available published breast cancer data on the interaction between the relevant SNPs for CYP2D6, CYP3A, CYP2B6, and CYP2C19 and the efficacy of tamoxifen, their role in individualisation of hormonal therapy and the role of the commercially available genotyping kits.
Copyright © 2010 Elsevier Ltd. All rights reserved.

PMID: 21185724 [PubMed - as supplied by publisher]
Tamoxifen, cytochrome P450 genes and breast cancer... [Breast. 2010] - PubMed result


http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WC2-51SMS8C-1&_user=10&_coverDate=12%2F24%2F2010&_rdoc=1&_fmt=high&_orig=search&_origin=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=89072c7e7bda7d044a339078971990a2&searchtype=a